Trial Profile
A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Sodium nitrite (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Aires Pharmaceuticals
- 08 Sep 2014 Primary endpoint (improvement in pulmonary vascular resistance) has been met, according to results reported in Mast Therapeutics media release.
- 08 Sep 2014 Top-line results published in Mast Therapeutics media release.
- 11 Apr 2014 New trial record